Reference — Maternal-Newborn
Women’s Health Screening Reference
The preventive screening nurses teach and coordinate — cervical (Pap/HPV), breast (mammography), and bone density — plus HPV vaccination. Exact ages and intervals vary by guideline; the patterns below are the high-yield ones.
Educational use only. Screening recommendations differ among professional organizations and change over time, and are individualized by risk. Always follow the current guideline and provider orders. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
Screening Schedule
| Screen | When (typical) | Key point |
|---|---|---|
| Cervical — Pap (cytology) | Begin at age 21; every 3 years (21–29) | Detects cervical cell changes; not done before 21 regardless of sexual activity |
| Cervical — Pap + HPV co-test | Ages 30–65: co-test every 5 years (or Pap alone q3y, or primary HPV q5y) | HPV is the cause of nearly all cervical cancer; co-testing extends the interval |
| Breast — mammography | Generally offered starting ~40–50, every 1–2 years (guidelines vary) | Primary screen for breast cancer; individualize by risk and guideline |
| Breast — clinical exam & self-awareness | Periodic; ongoing breast self-awareness | Report a new lump, skin/nipple change, or discharge; best done after menses when least tender |
| Bone density — DEXA | Women ≥ 65 (earlier if risk factors) | Screens for osteoporosis; menopausal estrogen loss accelerates bone loss |
HPV Vaccination
HPV causes nearly all cervical cancer and many other anogenital/oropharyngeal cancers. The vaccine is routinely recommended around ages 11–12 (can start at 9), ideally before any exposure, with catch-up through the mid-20s and shared decision-making to the mid-40s. It does not replace cervical screening — vaccinated patients still need Pap/HPV testing.
Reading an Abnormal Pap
| Term | Meaning |
|---|---|
| ASC-US | Atypical squamous cells of undetermined significance — the mildest abnormality; usually HPV-triaged or repeat |
| LSIL | Low-grade squamous intraepithelial lesion — mild dysplasia, often HPV-related; follow-up/colposcopy per protocol |
| HSIL | High-grade squamous intraepithelial lesion — moderate/severe dysplasia; colposcopy and treatment |
| Colposcopy | Magnified exam of the cervix with biopsy to evaluate abnormal Pap/HPV results |
NCLEX Pearls
- ✦Cervical (Pap) screening begins at 21 regardless of sexual-activity start; co-testing (Pap+HPV) every 5 years is an option at 30–65.
- ✦HPV causes nearly all cervical cancer — vaccinate early (ideally before exposure), but keep screening afterward.
- ✦Teach breast self-awareness: report a new lump, dimpling/skin change, nipple change, or discharge; examine after menses when least tender.
- ✦DEXA screens for osteoporosis (women ≥65, earlier with risk) — menopausal estrogen loss accelerates bone loss.
- ✦Any postmenopausal bleeding is abnormal and warrants evaluation — it is not a screening 'normal.'
Related Resources
Standards & sources
Fact-checked Jun 20, 2026This page is written to align with American College of Obstetricians and Gynecologists (ACOG) · AWHONN · American Academy of Pediatrics (AAP) — newborn. It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →